Global WholeHealth Partners, Corp (OTC:GWHP) Secures Global Distribution Rights to Sell the AstraZeneca COVID-19 Vaccine Anywhere in the World Pending FDA Approval as Biden Administration Stockpiles Vaccine

SAN CLEMENTE, CA / ACCESSWIRE / March 23, 2021 / Global WholeHealth Partners Corp, (OTC PINK:GWHP) a multinational supplier of over 70+ FDA approved tests including Dengue, Ebola, Zika, Malaria also offering one of the largest lines of tests for CoViD19 SARS2, is prepared to help in the fight against CoViD19 SARS2. With the vaccine rollout in progress, continued testing for COVID-19 is imperative and needs to remain a top priority to stop the spread of this deadly virus.

Global WholeHealth Partners, Corp (OTC PINK:GWHP) Secures Distribution Rights to sell the AstraZeneca COVID-19 Vaccine anywhere in the world pending FDA Approval as Biden Administration Increases Stockpile in preparation of a quick roll out.

Charles Strongo, CEO of Global WholeHealth Partners, Corp. said, “We were so impressed by the progress that AstraZeneca has made thus far with their vaccine, that we (Global) have secures the distribution rights to sell this vaccine anywhere in the world.”

“We think the Biden Administration is being strategically proactive with their plan to accumulate the AstraZeneca vaccines ahead of time,” Charles Strongo commented

White House press secretary Jen Psaki recently said “We want to be oversupplied and over prepared,” saying Biden wanted contingencies in the event of any unforeseen issues with the existing production timeline.

A copy of the Global WholeHealth Partners, Corp 8K filing dated 03/02/2021 related to the distribution rights of the AstraZeneca vaccine can be found here.

“The CDC is still recommending that individuals who are already fully vaccinated for the COVID-19 virus continue to get tested if they are experiencing any of the symptoms,” Charles Strongo reiterated.

CDC Recommendations for Fully Vaccinated People can be found here.

“There is no better way to Stop the Spread of COVID-19 and it’s various mutated strains then by utilizing the rapid antibody test kits that we offer to accurately detect those who have become infected and having them immediately quarantine,” says Charles Strong, CEO of Global WholeHealth Partners, Corp.

Global WholeHealth Partners recognizes that there is a crucial need for faster testing and faster results when it comes to fighting the COVID. Global WholeHealth Partners knows that the quicker the test results can be reviewed by a Front-Line Healthcare Worker, the quicker we can stop the spread of this disease.

With results in minutes versus hours or days with other diagnostic kits, the more lives that can be saved with the only FDA authorized COVID-19 POC serology Point of Care Test. With the new fingerstick test, healthcare providers can prick a patient’s finger and get results in minutes without having to wait for venous blood. Global WholeHealth Partners will be able to distribute these tests to more urgent cares, hospitals, and – to help curb the spread of CoViD19 SARS2.

Global Wholehealth Partners Corp. provides cutting edge technology using In-vitro Diagnostic (IVD) Real-Time PCR Machines for detection of SARS-CoV-2 IgM/IgG antibodies in human serum, plasma, or whole blood. It has led the fight against vector borne terminal diseases such as Ebola, ZIKA, Dengue, Malaria, Influenza and Tuberculosis, Corona Viruses, and among other vector borne diseases. The company was founded on March 7, 2013 and is headquartered in San Clemente, CA.

GWHP develops, manufactures, and markets in vitro diagnostic (IVD) tests for OTC, or consumer-use as well as professional rapid diagnostic point-of-care (POC) test kits for hospitals, physicians’ offices, and medical clinics in the US and abroad. Notably, GWHP offers a CE Mark for its high quality, rapid antibody test for COVID-19 and an EUA filing with the FDA is pending approval. In the interim, the US Navy in California has been using the test during 2Q20 and the Company has the capacity to deliver hundreds of thousands of tests, ramping up to 1 million per day. Currently, the Company has 56 products FDA approved and many are Approved for OTC use, and 9 POC products approved by the FDA.

Disclaimer:

The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time

Media Contact:

Name: Charles Strongo,
CEO, Global WholeHealth Partners Corp.
Email: Sales@gwhpcorp.com; Sales
CStrongo@gwhpcorp.com Media
www.gwhpcorp.com

This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

https://www.cdc.gov/coronavirus/2019-ncov/vaccines/fully-vaccinated-guidance.html

SOURCE: Global WholeHealth Partners Corp,

View source version on accesswire.com:
https://www.accesswire.com/636843/Global-WholeHealth-Partners-Corp-OTCGWHP-Secures-Global-Distribution-Rights-to-Sell-the-AstraZeneca-COVID-19-Vaccine-Anywhere-in-the-World-Pending-FDA-Approval-as-Biden-Administration-Stockpiles-Vaccine